<DOC>
	<DOCNO>NCT02366949</DOCNO>
	<brief_summary>Determine safety , tolerability , maximum tolerate dose ( MTD ) , recommend Phase 2 dose ( RP2D ) oral BAY 1217389 give combination intravenous ( IV ) paclitaxel use intermittent dosing schedule ( 2 day / 5 day ) subject advanced malignancy .</brief_summary>
	<brief_title>Phase I Study Oral BAY 1217389 Combination With Intravenous Paclitaxel</brief_title>
	<detailed_description>BAY 1217389 potent highly selective inhibitor monopolar spindle 1 ( MPS1 ) kinase activity . Human MPS1 serine threonine kinase , function core component spindle-assembly checkpoint ( SAC ) , key surveillance mechanism monitor attachment spindle microtubule kinetochore chromosome pro-metaphase halt transition anaphase chromosome bi-oriented , fully attach , correctly tense metaphase plate . MPS1 express mitosis phase cell cycle proliferate cell . Overexpression MPS1 observe several cancer cell line tumor type , include lung breast cancer . Established anti-mitotic drug vinca alkaloid , taxanes , epothilones activate SAC either destabilize stabilize spindle microtubule result mitotic arrest . Prolonged arrest mitosis force cell either mitotic exit without cytokinesis mitotic catastrophe lead cell death . In contrast , MPS1 inhibitor inactivate SAC accelerate progression cell mitosis eventually result severe chromosomal missegregation , mitotic catastrophe , cell death . Consequently , MPS1 inhibition lead failure cell arrest mitosis response anti-mitotic drug . Thus , combination microtubule-interfering agent MPS1 inhibition strongly increase chromosomal segregation error cell death therefore , constitute efficient strategy selectively eliminate tumor cell . MPS1 inhibition combination microtubule-interfering agent expect improve therapeutic efficacy anti-mitotic drug overcome paclitaxel resistance . The primary objective study : - Determine safety , tolerability , maximum tolerate dose ( MTD ) , recommend Phase 2 dose ( RP2D ) oral BAY 1217389 give combination intravenous ( IV ) paclitaxel use intermittent dosing schedule ( 2 day / 5 day ) subject advanced malignancy . - Characterize pharmacokinetics ( PK ) oral BAY 1217389 IV paclitaxel . The exploratory objective study : - Determine preliminary clinical efficacy oral BAY 1217389 give combination IV paclitaxel compare paclitaxel give alone . - Determine pharmacodynamic ( PD ) target modulation effect ( decrease phosphorylated kinetochore-associated protein pKNL1 potentially biomarkers like activation p53 system ) oral BAY 1217389 mandatory pair fresh tumor biopsy ( mandatory pair fresh skin punch biopsy depend status subject accessibility tumor ) take Day 2 Cycle 1 ( C1D2 ) C1D3 . - Evaluate effect oral BAY 1217389 activation p53 blood sample PD biomarker ( blood sample take mandatory procedure monitor PD effect C1D 4 , C1D 3 , C1D 2 ) . - Evaluate effect BAY 1217389 level tumor-derived free circulate deoxyribonucleic acid ( DNA ) blood sample take first dose study treatment C1D3 , C1D8 , C1D15</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male female subject age &gt; /= 18 year . Study population : For doseescalation cohort : Subjects histologically cytologically confirm advanced malignancy ( solid tumor ) , refractory standard therapy , standard therapy available For expansion cohort : Subjects advance , histologically cytologically confirm triplenegative breast cancer ( TNBC ) , refractory standard therapy , standard therapy available , subject actively refuse standard treatment / , judgment investigator , experimental treatment clinically acceptable . Subjects must evaluable measurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy least 12 week . Adequate bone marrow , liver , renal function . Known hypersensitivity study drug excipients preparation agent give association study . Evidence peripheral neuropathy Grade &gt; 2 . History cardiac disease : congestive heart failure New York Heart Association ( NYHA ) class &gt; II , unstable angina ( anginal symptom rest ) , newonset angina ( within past 3 month study entry ) , myocardial infarction within past 3 month study entry , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker , calcium channel blocker , digoxin permit ) . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg , despite optimal medical management . Moderate severe hepatic impairment , i.e . ChildPugh class B C. History human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>MPS-1 inhibitor</keyword>
	<keyword>Oncology</keyword>
</DOC>